Navigation Links
Helios Education Foundation invests $6.5 million
Date:1/30/2008

summer internship program, which included a stipend for students. This led to a sizable increase in the number of qualified student applications from around the State. The $6.5 million endowment enables TGen to extend its competitive internship program for 25 years and provide a stipend and other support for students. The Helios Scholars Program at TGen also encourages student diversity, with upwards of 20 percent of the interns coming from underrepresented populations.

"We are excited to continue and expand our partnership with the Helios Education Foundation," said TGen president, Dr. Jeffrey Trent. "Our shared commitment to training the next generation of researchers provides an unparalleled opportunity for Arizona and those students seeking hands-on training to augment their classroom experience. For many of these students, this experience will prove to be a defining moment in focusing their career choices across the biosciences.

Applications are now available on-line at the TGen website: http://www.tgen.org/intern. Interns must be a resident of Arizona or a full-time student at an Arizona-based high school, accredited college or university. The application deadline is March 14. Attributes that investigators consider in selecting students include a strong desire to conduct independent research, interests, academic achievement, curiosity, ambition, and aptitude for working independently and with a team. The application process is competitive, but many different backgrounds and abilities are represented among the students selected.

In addition to the stipends, Helios Education Foundation and TGen recognize each student as a Helios Scholar. The endowment also funds an end-of-the-summer symposium where students present their work to their peers, TGen staff, family and guests. Additionally, the endowment provides six merit-based scholarships and supports several extra curricular activities to encou
'/>"/>

Contact: Amy Erickson
aerickson@tgen.org
602-343-8522
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Graduate Education in Physics: Which Way Forward?
2. Evolution education is a must says coalition of scientific and teaching organizations
3. Leading experts cite poor health and nutrition as major barrier to education in developing world
4. Stevens wins Excellence in Technology Education Award
5. Harold Mooney and Peter Raven, winners of the BBVA Foundation Award for Conservation Biology
6. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators
7. CONRAD receives $28.5M Gates Foundation grant for HIV prevention research
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. Life-saving clean water project secures $13M from Bill & Melinda Gates Foundation
10. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
11. Simons Foundation awards Emory scientists $3M for autism gene research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2